Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
With a diagnosis of RA classified by ACR 1987 revised criteria with symptoms for at least 6 months
Functional status class I, II, III according to the ACR 1991 revised classification criteria
Patients have to have been treated with MTX at the maximum tolerated dose for at least 3 months, and be on a stable dose and route of administration for at least 2 months prior to study entry
Disease activity criteria of minimum 6 out of 28 tender and swollen joints at baseline
You may not be if
With current use of DMARDs other than MTX. DMARDs include but are not limited to: biologic agents, thiolates (D-penicillamine, thiopronine), sulfasalazine, gold compounds, antimalarials, cyclosporine A, azathioprine, leflunomide and alkylating agents such as cyclophosphamide
With any DMRAD treatment used in combination with methotrexate within 1 month prior to study entry. In case of infliximab and leflunomide, a washout period of 2 months is required
With any therapy by intra-articular injection, including intra-articular corticosteroid use within 1 month prior to study entry
